Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Receives Consensus Rating of "Moderate Buy" from Analysts

Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Get Free Report) have earned an average rating of "Moderate Buy" from the six analysts that are covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $6.25.

A number of brokerages recently weighed in on XERS. Leerink Partners boosted their price objective on shares of Xeris Biopharma from $5.00 to $6.00 and gave the company an "outperform" rating in a research report on Friday, March 7th. Wall Street Zen downgraded shares of Xeris Biopharma from a "buy" rating to a "hold" rating in a research report on Thursday, May 22nd. HC Wainwright reaffirmed a "buy" rating and set a $8.00 price objective (up previously from $6.60) on shares of Xeris Biopharma in a research report on Friday, March 7th. Piper Sandler restated a "neutral" rating and issued a $4.00 target price (up previously from $3.00) on shares of Xeris Biopharma in a research report on Friday, March 7th. Finally, Craig Hallum upped their target price on shares of Xeris Biopharma from $5.00 to $6.50 and gave the stock a "buy" rating in a research report on Friday, March 7th.

Xeris Biopharma Stock Up 1.7%

Shares of NASDAQ XERS traded up $0.08 during trading on Tuesday, hitting $4.54. 616,654 shares of the company traded hands, compared to its average volume of 1,963,829. The company has a 50-day moving average price of $4.57 and a 200-day moving average price of $4.06. Xeris Biopharma has a 1 year low of $2.03 and a 1 year high of $6.07. The firm has a market capitalization of $709.21 million, a P/E ratio of -10.08 and a beta of 1.10.

Xeris Biopharma (NASDAQ:XERS - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.06) EPS for the quarter, topping analysts' consensus estimates of ($0.07) by $0.01. The firm had revenue of $57.80 million during the quarter, compared to analyst estimates of $57.61 million. Research analysts predict that Xeris Biopharma will post -0.41 EPS for the current fiscal year.

Insider Transactions at Xeris Biopharma

In other Xeris Biopharma news, insider Beth Hecht sold 40,000 shares of Xeris Biopharma stock in a transaction that occurred on Thursday, March 20th. The shares were sold at an average price of $5.43, for a total value of $217,200.00. Following the transaction, the insider now owns 1,353,510 shares of the company's stock, valued at approximately $7,349,559.30. The trade was a 2.87% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 6.47% of the stock is owned by corporate insiders.

Institutional Trading of Xeris Biopharma

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. NewEdge Advisors LLC acquired a new position in shares of Xeris Biopharma in the fourth quarter valued at $34,000. Apella Capital LLC acquired a new stake in Xeris Biopharma during the first quarter worth about $55,000. Xponance Inc. acquired a new stake in Xeris Biopharma during the first quarter worth about $57,000. FORA Capital LLC acquired a new stake in Xeris Biopharma during the first quarter worth about $60,000. Finally, FNY Investment Advisers LLC acquired a new stake in Xeris Biopharma during the first quarter worth about $63,000. 42.75% of the stock is owned by institutional investors.

Xeris Biopharma Company Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.